Javlor
(vinflunine)Phase 3Small molecule
Bristol-Myers SquibbVinflunine is used to treat advanced bladder cancer in patients who have already received other chemotherapy treatments. It works by stopping cancer cells from dividing and growing.[1] Javlor is currently being investigated across 1 indication[3], with its most advanced program in Phase 3.[1]
Javlor is one of 21 small molecule programs targeting Urothelial Cancer. It is currently in Phase 3.
1
Indications
26
Total Trials
2
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
21 competitors in Urothelial Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Padcev
PfizerPhase 3
Balversa
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Imjudo
AstraZenecaPhase 3
Taxotere
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
MEDI4736
AstraZenecaPhase 3
Adriamycin
PfizerPhase 2
Ninlaro
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Bladder Cancer5 trials
Breast Cancer4 trials
Transitional Cell Carcinoma3 trials
Metastatic Urothelial Cancer2 trials
Urothelial Cancer2 trials
10 more indications
Advanced Cancer1 trial
Head and Neck Cancer1 trial
Small Cell Lung Cancer1 trial
Chemotherapy1 trial
Metastatic Solid Tumors1 trial
Advanced Urothelial Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for vinflunine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tubulin Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company